Released Nov 7, 2025, after the close
10-Q filed Nov 7, 2025, 38 days after period end · 0001493152-25-021287
Q3 2025 · 10-Q
Revenue—
Net Income-$1.24M-$1.24M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.15-$0.15 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$1,993,000N/M
Operating Cash Flowderived-$1,272,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | — | $487.00K | $51.00K | $0.00 |
| Net Income | -$1.24M | -$26.60M | -$5.59M | -$7.32M |
| EPS Diluted | -$0.15 | -$73.70 | -$1.03 | -$2.49 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR